Publications | VitroScan

Read more VitroScans Chemo Sensitivity Score predicts response to carboplatin and paclitaxel for ovarian cancer patients

5 June 2023

First publication of the predictive value of our ex vivo tumor testing platform at ASCO23.

Read more VitroScan presents the classification of cancer patients into responders and non responders to immunotherapy at AACR23

18 April 2023

VitroScan presents the classification of cancer patients into responders and non responders to immunotherapy at AACR23.

Read more VitroScan and Imuno are awarded a MIT grant to develop a platform to de-risk clinical development of immunotherapy for bladder cancer patients!

27 January 2023

We are are proud to announce that VitroScan and Imuno have been awarded the MIT R&D-Samenwerkingsproject Trial Booster (€992.600) by the province Zuid-Holland!

Read more VitroScan launches lung cancer trial

19 January 2023

VitroScan is thrilled to announce the launch of a new clinical trial for lung cancer patients

Read more Eurostars grants project funding for High-throughput ImmunoTherapy Screening- HITS

15 December 2022

A total grant sum of EUR €2.13 million, of which total subsidy ~ €995k has been awarded to a multidisciplinary project, named 'HITS'. The European consortium consist of four collaborating partners: VitroScan, Imuno, Biocopy, Utrecht University.

Read more VitroScan in the Dutch Journal 'Medische Oncologie'

9 December 2022

In June 2022, Willemijn Vader was interviewed by the Dutch Journal Medische Oncologie. She explained the development of the ex vivo 3D tumor testing platform and potential future application.

Read more VitroScan CEO Willemijn Vader is dedicated to delivering better cancer diagnoses

20 December 2021

This interview (Dutch) in Leidsch Dagblad is a good read to understand the goals of VitroScan and its significance to the quality of care for cancer patients.

Read more Tumor testing for advanced bladder cancer

31 August 2021

The Erasmus MC Bladder Cancer Centre and VitroScan BV join forces in the EVITA project: "Tumor testing for advanced bladder cancer to predict treatment efficacy" The project was awarded with an Erasmus MC-TKI-LSH Match Call (PPP) allowance.